Combination chemotherapy of ifosfamide, 5-fluorouracil, etoposide and cisplatin as perioperative treatment in lymph node positive bladder carcinoma patients treated by radical cystectomy

Objectives: To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5‐fluorouracil, etoposide and cisplatin (IFEP) in bladder cancer patients with regional lymph node metastases treated by radical cystectomy. Methods: We reviewed the medical records of 183...

Full description

Saved in:

Bibliographic Details
Published in	International journal of urology Vol. 15; no. 11; pp. 971 - 975
Main Authors	Komai, Yoshinobu, Fujii, Yasuhisa, Okubo, Yuhei, Yamamoto, Shinya, Kawakami, Satoru, Yonese, Junji, Fukui, Iwao
Format	Journal Article
Language	English
Published	Melbourne, Australia Blackwell Publishing Asia 01.11.2008
Subjects	Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use bladder cancer chemotherapy Cisplatin - administration & dosage Combined Modality Therapy Cystectomy Etoposide - administration & dosage Female Fluorouracil - administration & dosage Humans IFEP Ifosfamide - administration & dosage lymph node metastasis Lymphatic Metastasis Male Middle Aged radical cystectomy Survival Rate Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - surgery
Online Access	Get full text
ISSN	0919-8172 1442-2042 1442-2042
DOI	10.1111/j.1442-2042.2008.02160.x

Cover

Abstract	Objectives: To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5‐fluorouracil, etoposide and cisplatin (IFEP) in bladder cancer patients with regional lymph node metastases treated by radical cystectomy. Methods: We reviewed the medical records of 183 consecutive patients who underwent radical cystectomy for invasive urothelial carcinoma of the bladder. Of those, 26 patients with regional lymph node metastasis who were regarded as being rendered surgically disease‐free (pT1‐4, N1‐2, cM0) and treated with perioperative IFEP chemotherapy were the subjects of the present study. Results: Median follow‐up of 26 patients was 49 months (range 4–150). Grade 3 and 4 bone marrow toxicities were seen in 15 and four patients, respectively. Neither chemotherapy‐related death nor febrile neutropenia occurred. The 5‐year overall and cancer‐specific survival rate was 60% and 68%, respectively. The overall survival rate of the patients with pT4 disease was significantly worse than that of patients with pT1‐3. There were four N2 patients who survived for over 5 years free of disease. Conclusions: Perioperative IFEP therapy appeared to be effective in the treatment of lymph node positive bladder cancer patients who underwent radical cystectomy. Further study may be warranted.
AbstractList	Objectives:To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP) in bladder cancer patients with regional lymph node metastases treated by radical cystectomy. Methods:We reviewed the medical records of 183 consecutive patients who underwent radical cystectomy for invasive urothelial carcinoma of the bladder. Of those, 26 patients with regional lymph node metastasis who were regarded as being rendered surgically disease-free (pT1-4, N1-2, cM0) and treated with perioperative IFEP chemotherapy were the subjects of the present study. Results:Median follow-up of 26 patients was 49 months (range 4-150). Grade 3 and 4 bone marrow toxicities were seen in 15 and four patients, respectively. Neither chemotherapy-related death nor febrile neutropenia occurred. The 5-year overall and cancer-specific survival rate was 60% and 68%, respectively. The overall survival rate of the patients with pT4 disease was significantly worse than that of patients with pT1-3. There were four N2 patients who survived for over 5 years free of disease. Conclusions:Perioperative IFEP therapy appeared to be effective in the treatment of lymph node positive bladder cancer patients who underwent radical cystectomy. Further study may be warranted. To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP) in bladder cancer patients with regional lymph node metastases treated by radical cystectomy.OBJECTIVESTo evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP) in bladder cancer patients with regional lymph node metastases treated by radical cystectomy.We reviewed the medical records of 183 consecutive patients who underwent radical cystectomy for invasive urothelial carcinoma of the bladder. Of those, 26 patients with regional lymph node metastasis who were regarded as being rendered surgically disease-free (pT1-4, N1-2, cM0) and treated with perioperative IFEP chemotherapy were the subjects of the present study.METHODSWe reviewed the medical records of 183 consecutive patients who underwent radical cystectomy for invasive urothelial carcinoma of the bladder. Of those, 26 patients with regional lymph node metastasis who were regarded as being rendered surgically disease-free (pT1-4, N1-2, cM0) and treated with perioperative IFEP chemotherapy were the subjects of the present study.Median follow-up of 26 patients was 49 months (range 4-150). Grade 3 and 4 bone marrow toxicities were seen in 15 and four patients, respectively. Neither chemotherapy-related death nor febrile neutropenia occurred. The 5-year overall and cancer-specific survival rate was 60% and 68%, respectively. The overall survival rate of the patients with pT4 disease was significantly worse than that of patients with pT1-3. There were four N2 patients who survived for over 5 years free of disease.RESULTSMedian follow-up of 26 patients was 49 months (range 4-150). Grade 3 and 4 bone marrow toxicities were seen in 15 and four patients, respectively. Neither chemotherapy-related death nor febrile neutropenia occurred. The 5-year overall and cancer-specific survival rate was 60% and 68%, respectively. The overall survival rate of the patients with pT4 disease was significantly worse than that of patients with pT1-3. There were four N2 patients who survived for over 5 years free of disease.Perioperative IFEP therapy appeared to be effective in the treatment of lymph node positive bladder cancer patients who underwent radical cystectomy. Further study may be warranted.CONCLUSIONSPerioperative IFEP therapy appeared to be effective in the treatment of lymph node positive bladder cancer patients who underwent radical cystectomy. Further study may be warranted. To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP) in bladder cancer patients with regional lymph node metastases treated by radical cystectomy. We reviewed the medical records of 183 consecutive patients who underwent radical cystectomy for invasive urothelial carcinoma of the bladder. Of those, 26 patients with regional lymph node metastasis who were regarded as being rendered surgically disease-free (pT1-4, N1-2, cM0) and treated with perioperative IFEP chemotherapy were the subjects of the present study. Median follow-up of 26 patients was 49 months (range 4-150). Grade 3 and 4 bone marrow toxicities were seen in 15 and four patients, respectively. Neither chemotherapy-related death nor febrile neutropenia occurred. The 5-year overall and cancer-specific survival rate was 60% and 68%, respectively. The overall survival rate of the patients with pT4 disease was significantly worse than that of patients with pT1-3. There were four N2 patients who survived for over 5 years free of disease. Perioperative IFEP therapy appeared to be effective in the treatment of lymph node positive bladder cancer patients who underwent radical cystectomy. Further study may be warranted. Objectives: To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5‐fluorouracil, etoposide and cisplatin (IFEP) in bladder cancer patients with regional lymph node metastases treated by radical cystectomy. Methods: We reviewed the medical records of 183 consecutive patients who underwent radical cystectomy for invasive urothelial carcinoma of the bladder. Of those, 26 patients with regional lymph node metastasis who were regarded as being rendered surgically disease‐free (pT1‐4, N1‐2, cM0) and treated with perioperative IFEP chemotherapy were the subjects of the present study. Results: Median follow‐up of 26 patients was 49 months (range 4–150). Grade 3 and 4 bone marrow toxicities were seen in 15 and four patients, respectively. Neither chemotherapy‐related death nor febrile neutropenia occurred. The 5‐year overall and cancer‐specific survival rate was 60% and 68%, respectively. The overall survival rate of the patients with pT4 disease was significantly worse than that of patients with pT1‐3. There were four N2 patients who survived for over 5 years free of disease. Conclusions: Perioperative IFEP therapy appeared to be effective in the treatment of lymph node positive bladder cancer patients who underwent radical cystectomy. Further study may be warranted. Objectives: To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5‐fluorouracil, etoposide and cisplatin (IFEP) in bladder cancer patients with regional lymph node metastases treated by radical cystectomy. Methods: We reviewed the medical records of 183 consecutive patients who underwent radical cystectomy for invasive urothelial carcinoma of the bladder. Of those, 26 patients with regional lymph node metastasis who were regarded as being rendered surgically disease‐free (pT1‐4, N1‐2, cM0) and treated with perioperative IFEP chemotherapy were the subjects of the present study. Results: Median follow‐up of 26 patients was 49 months (range 4–150). Grade 3 and 4 bone marrow toxicities were seen in 15 and four patients, respectively. Neither chemotherapy‐related death nor febrile neutropenia occurred. The 5‐year overall and cancer‐specific survival rate was 60% and 68%, respectively. The overall survival rate of the patients with pT4 disease was significantly worse than that of patients with pT1‐3. There were four N2 patients who survived for over 5 years free of disease. Conclusions: Perioperative IFEP therapy appeared to be effective in the treatment of lymph node positive bladder cancer patients who underwent radical cystectomy. Further study may be warranted.
Author	Fujii, Yasuhisa Yonese, Junji Kawakami, Satoru Fukui, Iwao Komai, Yoshinobu Yamamoto, Shinya Okubo, Yuhei
Author_xml	– sequence: 1 givenname: Yoshinobu surname: Komai fullname: Komai, Yoshinobu organization: Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan – sequence: 2 givenname: Yasuhisa surname: Fujii fullname: Fujii, Yasuhisa organization: Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan – sequence: 3 givenname: Yuhei surname: Okubo fullname: Okubo, Yuhei organization: Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan – sequence: 4 givenname: Shinya surname: Yamamoto fullname: Yamamoto, Shinya organization: Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan – sequence: 5 givenname: Satoru surname: Kawakami fullname: Kawakami, Satoru organization: Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan – sequence: 6 givenname: Junji surname: Yonese fullname: Yonese, Junji organization: Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan – sequence: 7 givenname: Iwao surname: Fukui fullname: Fukui, Iwao organization: Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
BackLink	https://cir.nii.ac.jp/crid/1573105975496773248$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/18775029$$D View this record in MEDLINE/PubMed
BookMark	eNqNksFu1DAURSNURKeFX0BeIFbNYDtx7CxAQiNaWkawoWp3lmO_aDwkcWpnYPJr_TqcSSkSG-rFs613z32Sr0-So851kCSI4CWJ6912SfKcphTndEkxFktMSYGX-2fJ4rFxlCxwScpUEE6Pk5MQthiTjBLxIjkmgnOGablI7leurWynBus6pDfQumEDXvUjcjWytQu1aq2BM8TSutk573ZeaducIRhc70JsIdUZpG3om2jSIRVQD966WOL9J6DBgxpa6AYUu83Y9hvUuYhN9EFQNcoY8Egrr23nWoX6SEYgzCwYVI3IK2O1apAewwB6cO34MnleqybAq4f9NLk-__R99Tldf7u4XH1cp5oxhlNKK63rkvOMGsKMUYIKRTnNsOFEYJwRpgpakaJURSEMA8ErEJgYRoADMdlp8nb27b2720EYZGuDhqZRHbhdkEVZ5gRT_l9hTIrltBRR-PpBuKtaMLL3tlV-lH9iiQIxC7R3IXio_0qwnH6A3MopaDkFPfkKefgBch_RD_-g2g6HeAevbPMUg_ezwS_bwPjkwfLy6no6Rf7NzHfWxtlTJYxnBLOSs7wspiDy6Q3SWWZjnvvHMcr_kAXPOJM3Xy_k1ZfbQtyub-Q6-w3lS-dq
CitedBy_id	crossref_primary_10_1016_j_urolonc_2013_01_007 crossref_primary_10_1111_j_1442_2042_2008_02221_x
Cites_doi	10.1002/cncr.11370 10.1056/NEJM199706193362502 10.1200/JCO.2004.11.024 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 10.1200/JCO.2000.18.17.3068 10.1111/j.1442-2042.2004.00841.x 10.1200/JCO.2001.19.20.4005 10.1016/S0022-5347(05)66067-3 10.1056/NEJMoa022148 10.1007/s002800100320 10.1016/S0022-5347(05)67632-X 10.1200/JCO.2005.07.757 10.1016/j.juro.2006.11.094 10.1046/j.1464-410X.1997.00158.x 10.1016/S0140-6736(99)02292-8 10.1016/S0022-5347(17)36578-3 10.1093/jjco/hyh005 10.1200/JCO.1997.15.2.589 10.1200/JCO.2001.19.3.666 10.1016/0277-5379(91)90447-L 10.1016/0277-5379(87)90260-4
ContentType	Journal Article
Copyright	2008 The Japanese Urological Association
Copyright_xml	– notice: 2008 The Japanese Urological Association
DBID	BSCLL RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 7X8
DOI	10.1111/j.1442-2042.2008.02160.x
DatabaseName	Istex CiNii Complete CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic
DatabaseTitleList	AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE CrossRef
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1442-2042
EndPage	975
ExternalDocumentID	18775029 10_1111_j_1442_2042_2008_02160_x IJU2160 10024425317 ark_67375_WNG_JKX68XLW_L
Genre	article Journal Article
GroupedDBID	--- .3N .55 .GA .Y3 05W 0R~ 10A 1OB 1OC 29J 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHEFC AIACR AIAGR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBC EBD EBS EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 YFH YUY ZZTAW ~IA ~WT AAHHS ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE RYH AEUQT AFPWT WRC WUP AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 7X8
ID	FETCH-LOGICAL-c5550-22bccf97732d15dda828a27230d71800315a62b169a668d5e87be801d51e7e1d3
IEDL.DBID	DR2
ISSN	0919-8172 1442-2042
IngestDate	Fri Jul 11 03:11:18 EDT 2025 Fri Jul 11 06:54:09 EDT 2025 Mon Jul 21 05:56:16 EDT 2025 Wed Oct 01 04:28:46 EDT 2025 Thu Apr 24 23:12:23 EDT 2025 Wed Jan 22 16:26:08 EST 2025 Thu Jun 26 23:00:48 EDT 2025 Sun Sep 21 06:19:06 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	11
Language	English
License	http://onlinelibrary.wiley.com/termsAndConditions#vor
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c5550-22bccf97732d15dda828a27230d71800315a62b169a668d5e87be801d51e7e1d3
Notes	ark:/67375/WNG-JKX68XLW-L istex:0841EB3F2A866264ADD5DB6404A01B89BBDD63F1 ArticleID:IJU2160 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
PMID	18775029
PQID	20054298
PQPubID	23462
PageCount	5
ParticipantIDs	proquest_miscellaneous_69941027 proquest_miscellaneous_20054298 pubmed_primary_18775029 crossref_primary_10_1111_j_1442_2042_2008_02160_x crossref_citationtrail_10_1111_j_1442_2042_2008_02160_x wiley_primary_10_1111_j_1442_2042_2008_02160_x_IJU2160 nii_cinii_1573105975496773248 istex_primary_ark_67375_WNG_JKX68XLW_L
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	November 2008
PublicationDateYYYYMMDD	2008-11-01
PublicationDate_xml	– month: 11 year: 2008 text: November 2008
PublicationDecade	2000
PublicationPlace	Melbourne, Australia
PublicationPlace_xml	– name: Melbourne, Australia – name: Australia
PublicationTitle	International journal of urology
PublicationTitleAlternate	Int. J. Urol
PublicationTitle_FL	Int. J. Urol
PublicationYear	2008
Publisher	Blackwell Publishing Asia
Publisher_xml	– name: Blackwell Publishing Asia
References	von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000; 18: 3068-77. Millikan R, Dinney C, Swanson D, Sweeney P et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol. 2001; 19: 4005-13. Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J. Urol. 2001; 166: 19-23. Herr HW. The concept of lymph node density - is it ready for clinical practice? J. Urol. 2007; 177: 1273-5. Ennis RD, Petrylak DP, Singh P et al. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer. J. Urol. 2000; 163: 1413-18. Kitahara S, Fukui I, Higashi Y et al. A randomized trial of chemotherapy of advanced prostatic cancer with ifosfamide alone versus ifosfamide, 5-fluorouracil and cisplatin (preliminary report). Nippon Gan Chiryo Gakkai Shi 1988; 23: 2507-13. Takahashi A, Tsukamoto T, Tobisu K et al. Radical cystectomy for invasive bladder cancer: results of multi-institutional pooled analysis. Jpn. J. Clin. Oncol. 2004; 34: 14-19. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005; 23: 4602-8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14. Suzuki S, Shinohara N, Harabayashi T, Sato S, Abe T, Koyanagi T. Impact of adjuvant systemic chemotherapy on postoperative survival in patients with high-risk urothelial cancer. Int. J. Urol. 2004; 11: 456-60. Witte RS, Elson P, Bono B et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J. Clin. Oncol. 1997; 15: 589-93. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 2001; 19: 666-75. Maezawa T, Yonese J, Tsukamoto T, Ishii N, Fukui I. Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy. Nippon Hinyokika Gakkai Zasshi 2002; 93: 727-35. Hartmann LC, Tschetter LK, Habermann TM et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N. Engl. J. Med. 1997; 336: 1776-80. Grossman HB, Natale RB, Tangen CM, Speights VO et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 2003; 349: 859-66. Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol. 1992; 148: 302-6. Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat. Rep. 1979; 63: 1459-73. Boutan-Laroze A, Mahjoubi M, Droz JP et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. Eur. J. Cancer 1991; 27: 1690-4. Galligioni E, Canobbio L, Figoli F et al. Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study. Eur. J. Cancer Clin. 1987; 23: 657-61. Fukui I, Izutani T, Yonese J, Oyama H, Kawai T. Preliminary ligation of vascular pedicles in male radical cystectomy. Br. J. Urol. 1997; 79: 641-2. Herr HW, Faulkner JR, Grossman HB et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J. Clin. Oncol. 2004; 22: 2781-9. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354:533-40. Frank I, Cheville JC, Blute ML et al. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer 2003; 97: 2425-31. Fukui I, Yonese J, Tsukamoto T et al. Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer. Cancer Chemother. Pharmacol. 2001; 48:88-93. 2001; 166 2004; 11 2004; 22 1987; 23 1997; 336 1991; 27 2000; 18 2003; 349 1997; 15 2007; 177 1997; 79 2004; 34 1992; 148 2001; 19 1981; 47 1988; 23 2000; 163 2001; 48 2002; 93 1999; 354 1979; 63 2003; 97 2005; 23 1988 e_1_2_5_26_2 e_1_2_5_24_2 e_1_2_5_25_2 e_1_2_5_22_2 e_1_2_5_23_2 e_1_2_5_20_2 e_1_2_5_21_2 Kitahara S (e_1_2_5_12_2) 1988; 23 e_1_2_5_14_2 e_1_2_5_13_2 e_1_2_5_9_2 e_1_2_5_8_2 e_1_2_5_7_2 e_1_2_5_10_2 e_1_2_5_6_2 e_1_2_5_5_2 e_1_2_5_4_2 e_1_2_5_11_2 e_1_2_5_3_2 e_1_2_5_2_2 e_1_2_5_18_2 e_1_2_5_19_2 Skinner DG (e_1_2_5_17_2) 1988 Schabel FM (e_1_2_5_15_2) 1979; 63 Maezawa T (e_1_2_5_16_2) 2002; 93
References_xml	– reference: Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J. Urol. 2001; 166: 19-23. – reference: Ennis RD, Petrylak DP, Singh P et al. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer. J. Urol. 2000; 163: 1413-18. – reference: Witte RS, Elson P, Bono B et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J. Clin. Oncol. 1997; 15: 589-93. – reference: Fukui I, Izutani T, Yonese J, Oyama H, Kawai T. Preliminary ligation of vascular pedicles in male radical cystectomy. Br. J. Urol. 1997; 79: 641-2. – reference: Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 2001; 19: 666-75. – reference: Herr HW, Faulkner JR, Grossman HB et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J. Clin. Oncol. 2004; 22: 2781-9. – reference: Millikan R, Dinney C, Swanson D, Sweeney P et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol. 2001; 19: 4005-13. – reference: Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14. – reference: von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005; 23: 4602-8. – reference: Boutan-Laroze A, Mahjoubi M, Droz JP et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. Eur. J. Cancer 1991; 27: 1690-4. – reference: Maezawa T, Yonese J, Tsukamoto T, Ishii N, Fukui I. Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy. Nippon Hinyokika Gakkai Zasshi 2002; 93: 727-35. – reference: Frank I, Cheville JC, Blute ML et al. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer 2003; 97: 2425-31. – reference: Fukui I, Yonese J, Tsukamoto T et al. Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer. Cancer Chemother. Pharmacol. 2001; 48:88-93. – reference: Galligioni E, Canobbio L, Figoli F et al. Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study. Eur. J. Cancer Clin. 1987; 23: 657-61. – reference: Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat. Rep. 1979; 63: 1459-73. – reference: Suzuki S, Shinohara N, Harabayashi T, Sato S, Abe T, Koyanagi T. Impact of adjuvant systemic chemotherapy on postoperative survival in patients with high-risk urothelial cancer. Int. J. Urol. 2004; 11: 456-60. – reference: Kitahara S, Fukui I, Higashi Y et al. A randomized trial of chemotherapy of advanced prostatic cancer with ifosfamide alone versus ifosfamide, 5-fluorouracil and cisplatin (preliminary report). Nippon Gan Chiryo Gakkai Shi 1988; 23: 2507-13. – reference: Grossman HB, Natale RB, Tangen CM, Speights VO et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 2003; 349: 859-66. – reference: von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000; 18: 3068-77. – reference: Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol. 1992; 148: 302-6. – reference: Takahashi A, Tsukamoto T, Tobisu K et al. Radical cystectomy for invasive bladder cancer: results of multi-institutional pooled analysis. Jpn. J. Clin. Oncol. 2004; 34: 14-19. – reference: Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354:533-40. – reference: Hartmann LC, Tschetter LK, Habermann TM et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N. Engl. J. Med. 1997; 336: 1776-80. – reference: Herr HW. The concept of lymph node density - is it ready for clinical practice? J. Urol. 2007; 177: 1273-5. – volume: 23 start-page: 657 year: 1987 end-page: 61 article-title: Cisplatin and 5‐fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study publication-title: Eur. J. Cancer Clin – volume: 19 start-page: 4005 year: 2001 end-page: 13 article-title: Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M‐VAC versus cystectomy with both preoperative and postoperative M‐VAC publication-title: J. Clin. Oncol – volume: 48 start-page: 88 year: 2001 end-page: 93 article-title: Combination chemotherapy with ifosfamide, 5‐fluorouracil, etoposide and cisplatin for metastatic urothelial cancer publication-title: Cancer Chemother. Pharmacol – volume: 166 start-page: 19 year: 2001 end-page: 23 article-title: Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy publication-title: J. Urol – volume: 63 start-page: 1459 year: 1979 end-page: 73 article-title: cis‐Dichlorodiammineplatinum(II): combination chemotherapy and cross‐resistance studies with tumors of mice publication-title: Cancer Treat. Rep – volume: 354 start-page: 533 year: 1999 end-page: 40 article-title: Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle‐invasive bladder cancer: a randomised controlled trial. International collaboration of trialists publication-title: Lancet – volume: 18 start-page: 3068 year: 2000 end-page: 77 article-title: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study publication-title: J. Clin. Oncol – volume: 15 start-page: 589 year: 1997 end-page: 93 article-title: Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma publication-title: J. Clin. Oncol – volume: 34 start-page: 14 year: 2004 end-page: 19 article-title: Radical cystectomy for invasive bladder cancer: results of multi‐institutional pooled analysis publication-title: Jpn. J. Clin. Oncol – volume: 47 start-page: 207 year: 1981 end-page: 14 article-title: Reporting results of cancer treatment publication-title: Cancer – volume: 336 start-page: 1776 year: 1997 end-page: 80 article-title: Granulocyte colony‐stimulating factor in severe chemotherapy‐induced afebrile neutropenia publication-title: N. Engl. J. Med – volume: 23 start-page: 4602 year: 2005 end-page: 8 article-title: Long‐term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer publication-title: J. Clin. Oncol – volume: 93 start-page: 727 year: 2002 end-page: 35 article-title: Combination chemotherapy with ifosfamide, 5‐fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy publication-title: Nippon Hinyokika Gakkai Zasshi – volume: 148 start-page: 302 year: 1992 end-page: 6 article-title: Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study publication-title: J. Urol – volume: 163 start-page: 1413 year: 2000 end-page: 18 article-title: The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer publication-title: J. Urol – volume: 19 start-page: 666 year: 2001 end-page: 75 article-title: Radical cystectomy in the treatment of invasive bladder cancer: long‐term results in 1,054 patients publication-title: J. Clin. Oncol – volume: 27 start-page: 1690 year: 1991 end-page: 4 article-title: M‐VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience publication-title: Eur. J. Cancer – volume: 349 start-page: 859 year: 2003 end-page: 66 article-title: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer publication-title: N. Engl. J. Med – volume: 79 start-page: 641 year: 1997 end-page: 2 article-title: Preliminary ligation of vascular pedicles in male radical cystectomy publication-title: Br. J. Urol – volume: 11 start-page: 456 year: 2004 end-page: 60 article-title: Impact of adjuvant systemic chemotherapy on postoperative survival in patients with high‐risk urothelial cancer publication-title: Int. J. Urol – volume: 23 start-page: 2507 year: 1988 end-page: 13 article-title: A randomized trial of chemotherapy of advanced prostatic cancer with ifosfamide alone versus ifosfamide, 5‐fluorouracil and cisplatin (preliminary report) publication-title: Nippon Gan Chiryo Gakkai Shi – volume: 177 start-page: 1273 year: 2007 end-page: 5 article-title: The concept of lymph node density – is it ready for clinical practice? publication-title: J. Urol – volume: 22 start-page: 2781 year: 2004 end-page: 9 article-title: Surgical factors influence bladder cancer outcomes: a cooperative group report publication-title: J. Clin. Oncol – volume: 97 start-page: 2425 year: 2003 end-page: 31 article-title: Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome publication-title: Cancer – start-page: 607 year: 1988 end-page: 21 – ident: e_1_2_5_21_2 doi: 10.1002/cncr.11370 – ident: e_1_2_5_24_2 doi: 10.1056/NEJM199706193362502 – ident: e_1_2_5_26_2 doi: 10.1200/JCO.2004.11.024 – ident: e_1_2_5_19_2 doi: 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 – ident: e_1_2_5_11_2 doi: 10.1200/JCO.2000.18.17.3068 – ident: e_1_2_5_3_2 doi: 10.1111/j.1442-2042.2004.00841.x – ident: e_1_2_5_5_2 doi: 10.1200/JCO.2001.19.20.4005 – volume: 63 start-page: 1459 year: 1979 ident: e_1_2_5_15_2 article-title: cis‐Dichlorodiammineplatinum(II): combination chemotherapy and cross‐resistance studies with tumors of mice publication-title: Cancer Treat. Rep – ident: e_1_2_5_20_2 doi: 10.1016/S0022-5347(05)66067-3 – ident: e_1_2_5_6_2 doi: 10.1056/NEJMoa022148 – ident: e_1_2_5_8_2 doi: 10.1007/s002800100320 – ident: e_1_2_5_10_2 doi: 10.1016/S0022-5347(05)67632-X – ident: e_1_2_5_25_2 doi: 10.1200/JCO.2005.07.757 – ident: e_1_2_5_23_2 doi: 10.1016/j.juro.2006.11.094 – volume: 93 start-page: 727 year: 2002 ident: e_1_2_5_16_2 article-title: Combination chemotherapy with ifosfamide, 5‐fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy publication-title: Nippon Hinyokika Gakkai Zasshi – ident: e_1_2_5_18_2 doi: 10.1046/j.1464-410X.1997.00158.x – start-page: 607 volume-title: Diagnosis and Management of Genitourinary Cancer year: 1988 ident: e_1_2_5_17_2 – ident: e_1_2_5_9_2 doi: 10.1016/S0140-6736(99)02292-8 – ident: e_1_2_5_7_2 doi: 10.1016/S0022-5347(17)36578-3 – volume: 23 start-page: 2507 year: 1988 ident: e_1_2_5_12_2 article-title: A randomized trial of chemotherapy of advanced prostatic cancer with ifosfamide alone versus ifosfamide, 5‐fluorouracil and cisplatin (preliminary report) publication-title: Nippon Gan Chiryo Gakkai Shi – ident: e_1_2_5_22_2 doi: 10.1093/jjco/hyh005 – ident: e_1_2_5_13_2 doi: 10.1200/JCO.1997.15.2.589 – ident: e_1_2_5_2_2 doi: 10.1200/JCO.2001.19.3.666 – ident: e_1_2_5_4_2 doi: 10.1016/0277-5379(91)90447-L – ident: e_1_2_5_14_2 doi: 10.1016/0277-5379(87)90260-4
SSID	ssj0013218
Score	1.8064704
Snippet	Objectives: To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5‐fluorouracil, etoposide and cisplatin (IFEP) in... Objectives: To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5‐fluorouracil, etoposide and cisplatin (IFEP) in... To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP) in bladder... Objectives:To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP) in...
SourceID	proquest pubmed crossref wiley nii istex
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	971
SubjectTerms	Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use bladder cancer chemotherapy Cisplatin - administration & dosage Combined Modality Therapy Cystectomy Etoposide - administration & dosage Female Fluorouracil - administration & dosage Humans IFEP Ifosfamide - administration & dosage lymph node metastasis Lymphatic Metastasis Male Middle Aged radical cystectomy Survival Rate Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - surgery
Title	Combination chemotherapy of ifosfamide, 5-fluorouracil, etoposide and cisplatin as perioperative treatment in lymph node positive bladder carcinoma patients treated by radical cystectomy
URI	https://api.istex.fr/ark:/67375/WNG-JKX68XLW-L/fulltext.pdf https://cir.nii.ac.jp/crid/1573105975496773248 https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1442-2042.2008.02160.x https://www.ncbi.nlm.nih.gov/pubmed/18775029 https://www.proquest.com/docview/20054298 https://www.proquest.com/docview/69941027
Volume	15
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1442-2042 dateEnd: 20241004 omitProxy: true ssIdentifier: ssj0013218 issn: 0919-8172 databaseCode: ABDBF dateStart: 19990201 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0919-8172 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1442-2042 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013218 providerName: Wiley-Blackwell
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtQwFLWgSIgN70eAgheIVVORh-1kiRClDG0XiFFnF_kVKZpMPEpmJKarfgIfxNfwJdzrZIZ2VKEKsYlGmdwkjo_tc6-Prwl5A0xI5FqrkCXGhCnUepgrzsJIW6ZLAI2UGNA_PuGH43Q0YZNB_4RrYfr8EJuAG7YM319jA5eq22rkuLQEUDdIImOMlCCfjBLmZ2y_xhcmFHyoD0ZHjHqJLVHPlTe6NFLdwo8Op242VXUVGb3Mbf3gdHCPTNfF6jUp0_3lQu3rs62Mj_-n3PfJ3YHD0vc96B6QG7Z5SG4fD7P0j8hP6GTA4fZ1TgEUs2GV14q6klal6zCqYuweZb_Of5T10rVwR6mreo_ahUMZmbFUNobqqpujVq-hsqOYktnNbZ-pnG4E8hT-rVeASdo4MOtFaHCBqrFPbanGzZIaN5N0SCHb9bbWULWirfTzVFRjQmu9cLPVYzI--Pjtw2E47BIRagbuVRjHSusSaGwSm4gZI8GHlLEA18rAuIudFpM8VhHPJeeZYTYTysK4bFhkhY1M8oTsNK6xzwg11mT6nUxKLnWqEKYow2FAcjKgoToOiFgjotBDCnXcyaMuLrpSaVxg5QwbfGLlFN8DEm0s530akWvYvPWg2xjIdooyPMGK05NPxejLhGeTo9PiKCC7gEp4IzxGTCTImQU4_hw_SpoF5PUarwV0HjgjJBvrlh0-Dvcr-8sVPM9T4KAiIE97oP95_UwA24zzgHAP12uXq_g8GuOv5_9q-ILc8aodvyL0JdlZtEu7C9RwoV75Rv8bukhUow
linkProvider	Wiley-Blackwell
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELaglYAL_z8BSn1AnJqqcWI7OSKgbLe7e0BddW-RYztS1GyySrISy4lH4IF4Gp6EmSS7tKsKVYhLtMpmkjj-PP5mPJ4h5C0wIRlpnbjcN8YNoNfdKBHc9bTlOgXQKIUO_fFEDKbBcMZnfTkg3AvT5YfYONxwZLT6Ggc4OqS3RjnuLQHY9TGRDF0lQCh3cbkOR-nHL-zSkkLr7IP5Ef1ecius59o7XZmrdvGzw6nbRZZdR0evstt2ejp-QPJ1w7qolIvDZZMc6m9bOR__U8sfkvs9jaXvO9w9Irds8ZjcGfcL9U_IT9AzYHO33U4BF_N-o9eKlinN0rJGx4qxB5T_-v4jzZdlBXdUOssPqG1KjCQzlqrCUJ3VCwzXK6iqKWZlLhe2S1ZONzHyFP7NVwBLWpQg1sWhwQVJjmq1ohrrJRXlXNE-i2zdyVpDkxWtVLtURTXmtNZNOV89JdPjT2cfBm5fKMLVHCwsl7FE6xSYrM-Mx41RYEYqJsG6MjD1ot7iSrDEE5ESIjTchjKxMDUb7llpPeM_IztFWdgXhBprQn2k_FQoHSSIVIzE4cBzQmCimjlEriER6z6LOhbzyOPL1lTAYuycvsYndk781SHeRnLRZRK5gcy7FnUbAVVdYCSe5PH55HM8PJ2JcDY6j0cO2QNYwhvh0ePSR9oswfYX-FGC0CH7a8DGoD9wUUgVtlzW-DgsWfaXK0QUBUBDpUOed0j_8_qhBMLJIoeIFq83bld8Mpzir5f_KrhP7g7OxqN4dDI5fUXutUE87QbR12SnqZZ2D5hik7xpNcBv8qNYvw
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dbtMwFLZgkyZu-GcEGPMF4mqZiBPbySUCytZ1FUJU613k2I4UNU2qJJUoVzwCD8TT8CSck6RlqyY0IW6iKs1J4viz_Z3jz8eEvAImJCOtE5f7xrgB1LobJYK7nrZcpwAapTCgfz4WJ5NgOOXTXv-Ea2G6_BCbgBu2jLa_xga-MOlWI8elJYC6XhLJMFICfHI3EOBsIUH6zC7NKLSxPhgeMewlt1Q9197pylC1i18dTt0usuw6NnqV3Laj0-Aema3L1YlSZsfLJjnW37ZSPv6fgt8nd3sSS992qHtAbtniIdk776fpH5Gf0MuAx91WOgVUzPtlXitapjRLyxrDKsYeUf7r-480X5YV3FHpLD-itilRR2YsVYWhOqsXKNYrqKop5mQuF7ZLVU43CnkK_-YrACUtSjDrVGhwQZJjp1pRjbslFeVc0T6HbN3ZWkOTFa1UO1FFNWa01k05Xz0mk8GHL-9O3H6bCFdz8K9cxhKtU-CxPjMeN0aBE6mYBN_KwMCLvRZXgiWeiJQQoeE2lImFgdlwz0rrGf8J2SnKwj4l1FgT6jfKT4XSQYI4RR0OB5YTAg_VzCFyjYhY9znUcSuPPL7sSwUsxsrpd_jEyom_OsTbWC66PCI3sHndgm5joKoZ6vAkjy_GH-Ph2VSE09FFPHLIAaAS3giPHpc-kmYJnr_AjxKEDjlc4zWG3gOnhFRhy2WNj8MNy_5yhYiiAEiodMh-B_Q_rx9KoJsscoho4XrjcsWnwwn-evavhodk79P7QTw6HZ89J3daBU-7OvQF2WmqpT0AmtgkL9v2_xuOOFdu
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combination+chemotherapy+of+ifosfamide%2C+5-fluorouracil%2C+etoposide+and+cisplatin+as+perioperative+treatment+in+lymph+node+positive+bladder+carcinoma+patients+treated+by+radical+cystectomy&rft.jtitle=International+journal+of+urology&rft.au=Komai%2C+Yoshinobu&rft.au=Fujii%2C+Yasuhisa&rft.au=Okubo%2C+Yuhei&rft.au=Yamamoto%2C+Shinya&rft.date=2008-11-01&rft.eissn=1442-2042&rft.volume=15&rft.issue=11&rft.spage=971&rft_id=info:doi/10.1111%2Fj.1442-2042.2008.02160.x&rft_id=info%3Apmid%2F18775029&rft.externalDocID=18775029
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0919-8172&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0919-8172&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0919-8172&client=summon